Latest posts
-
XA Interactive Embraces ESP Techniques, Begins New Drilling Operations To Boost Production
ORLANDO, FL, September 20, 2023 – Holiday Island Holdings, Inc. (OTC PINK: HIHI) recently completed a reverse merger with XA Interactive, Inc., a prominent player in the secondary recovery oil and gas sector is pleased to announce the commencement of new drilling operations employing Electric Submersible Pump (ESP) techniques. These methods are set to amplify
-
Seminario Web gratuito “Desalination Latin America: Progress of Key Projects”
Organizador: Vostock Capital Preámbulo a la 6ta Conferencia y Exposición Internacional DESALINIZACIÓN AMÉRICA LATINA 2024, 13 -14 de marzo de 2024 Santiago, Chile El seminario web sobre desalinización se realizará el 19 de octubre de 2023 a las 10 am (-4 GMT), hora de Santiago de Chile. El idioma del seminario web es el inglés.
-
Free webinar “Desalination Latin America: Progress of Key Projects”
Organiser: Vostock Capital Prior to the 6th International Conference and Exhibition DESALINATION LATIN AMERICA 2024, 13-14 March 2024 Santiago, Chile The desalination webinar will be held on 19th October de 2023 at 10 am (-4 GMT) Santiago de Chile time. The webinar’s language is English. Register to get the webinar material in Spanish. Free registration: https://vostockcapital.zoom.us/webinar/register/WN_3MvVVpGwRaOy8MiU8zSTLw#/registration/?from=media
-
NATURAL HARMONY FOODS INC. ANNOUNCES NEW STRATEGIC DIRECTION AND SETS THE STAGE FOR A REVOLUTION IN HEALTHCARE AND WELLNESS
NEW YORK, NY, September 19, 2023 -Publicly-held Natural Harmony Foods, Inc. (OTC: NHYF) (the Company) announces that following the change of control to Mr. Claudio Solitario, announced recently, the Company is now on a transformative path, signaling a compelling strategic direction. The Company’s transition under Claudio’s leadership signifies a dynamic shift towards innovation and growth,
-
BioStem Technologies Initiates Nationwide Launch of AmnioWrap2™ with Venture Medical
Leading wound market solutions provider will lead BioStem’s commercialization of AmnioWrap2™ AmnioWrap2 is a versatile allograft solution for wound applications POMPANO BEACH, FLORIDA, September 19, 2023 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placenta-derived biologics for advanced wound care, has entered an agreement
-
SKYX Appoints Widely-Respected Public Financial Markets Authority, Lenny Sokolow as Co-CEO
“I can’t emphasize enough how excited I am to join SKYX and introduce its growth opportunity to the financial institution segments during its inflection point. As evidence, I agreed for the majority of my compensation to be paid in SKYX’s stock and stock options.” Leonard (Lenny) Sokolow “Growth Opportunity at Key Inflection Point” HIGHLIGHTS ABOUT
-
BioStem Technologies Engages PCG Advisory for Strategic Investor Relations
POMPANO BEACH, FLORIDA, September 18, 2023 – BioStem Technologies Inc. (OTC: BSEM), an innovator in the development, manufacture, and commercialization of allografts for regenerative therapies, has engaged PCG Advisory, Inc., a leading investor relations and digital strategies firm, to serve as an advisor for investor relations and strategic communications. PCG Advisory will work closely with
-
XA Interactive Secures Funding to Expand Oil Drilling Operations
ORLANDO, FL, September 18, 2023 – Holiday Island Holdings, Inc. (OTC PINK: HIHI) recently completed a reverse-merger with XA Interactive, Inc., a prominent player in the secondary recovery oil and gas sector, is pleased to announce the successful securing of funding deals aimed at fueling the expansion of the company’s oil and gas operations. The
-
Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier
[et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”] Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte’s VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA, September 18, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data